Spring­Works and Seagen team up in mul­ti­ple myelo­ma; Mer­ck and Ei­sai build out Keytru­da/Lenvi­ma da­ta

Spring­Works has a new col­lab­o­ra­tion, and it’s one with a promi­nent phar­ma part­ner.

The Con­necti­cut biotech is team­ing up with Seagen on a new clin­i­cal tri­al to eval­u­ate the com­pa­ny’s gam­ma sec­re­tase in­hibitor nirogace­s­tat with SEA-BC­MA. Seagen’s can­di­date is a mon­o­clon­al an­ti­body tar­get­ing BC­MA, and the com­bo will look at pa­tients with re­lapsed or re­frac­to­ry mul­ti­ple myelo­ma.

The duo not­ed in a re­lease that “gam­ma sec­re­tase in­hi­bi­tion pre­vents the cleav­age and shed­ding of BC­MA from the sur­face of myelo­ma cells,” like­ly prov­ing the im­pe­tus for the deal. Un­der the deal, Seagen will spon­sor and con­duct the Phase I study ex­pect­ed to be­gin be­fore the end of 2021.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER